CSPC Pharmaceutical (HKG:1093) obtained approval to conduct a clinical trial of its SYH2046 tablets in China from the country's National Medical Products Administration, a Friday filing with the Hong Kong bourse said.

The indication for the trial approval is heart failure after acute myocardial infarction.

Preclinical studies have shown the drug to improve cardiac function and reduce adverse cardiac remodeling in disease animal models with a better safety profile.